Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.

Breast cancer research and treatment - 1 May 2008

Lei Haixin, Hemminki Kari, Johansson Robert, Altieri Andrea, Enquist Kerstin, Henriksson Roger, Lenner Per, Försti Asta

Abstract excerpt

Extracellular matrix degradation, mediated by the urokinase plasminogen activation (uPA) system, is a critical step in tumor invasion and metastasis. High tumor levels of uPA and its inhibitor PAI-1 have been correlated with poor prognosis in breast cancer. We examined whether genetic variation in the genes of the uPA system affect breast cancer susceptibility and prognosis. We genotyped eight potentially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homozygote

Share to Neoplasm Metastasis

Share to Plasminogen Activator Inhibitor 1

Share to Probability

Share to Treatment Outcome

Share to Urokinase-Type Plasminogen Activator

Source

Identifiers

PMID: 17616807
DOI: 10.1007/s10549-007-9635-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.PMID 17616807Read ↗

Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.Semantic proximity Read ↗

Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.Semantic proximity Read ↗

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.Semantic proximity Read ↗

Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.Semantic proximity Read ↗

Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.Semantic proximity Read ↗

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.Semantic proximity Read ↗

Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.Semantic proximity Read ↗

PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.Semantic proximity Read ↗

The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive RoleSemantic proximity Read ↗

Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.